Cancer treatment

Cancer treatment

Progenics Pharmaceuticals Expands Collaboration with Seattle Genetics to Develop Prostate Cancer Treatment

Progenics Pharmaceuticals, a biopharmaceutical company, has announced the expansion of its collaboration with Seattle Genetics to accelerate the development and manufacture of its prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC). The PSMA ADC is designed to target cancer cells with high specificity, potentially reducing toxicity to normal cells and tissues.